Vivace Therapeutics is focused on developing innovative cancer therapeutics by targeting the Hippo-YAP signaling pathway, which plays a crucial role in regulating cell proliferation, programmed cell death, and cell migration. The company has identified multiple novel small-molecule medicines that inhibit the YAP-TEAD transcription complex, a key effector of this pathway. In healthy cells, the Hippo-YAP pathway is essential for tissue regeneration and organ size control; however, mutations within this pathway can lead to oncogenic processes, driving various cancers such as mesothelioma, meningioma, and several others. Vivace's approach aims to create first-in-class therapeutics that can be used alone or in combination with existing treatments, addressing not only cancer but potentially other conditions like fibrotic diseases.

The company's lead candidate, VT3989, is a YAP-TEAD inhibitor currently undergoing clinical trials for patients with advanced solid tumors, particularly those with neurofibromatosis type 2 (NF2) mutations. Preclinical studies have shown that VT3989 enhances the efficacy of other targeted therapies, indicating its potential to improve treatment outcomes for patients. Vivace Therapeutics is committed to leveraging cutting-edge research and a strong scientific foundation to bring these promising therapies to market, with the goal of significantly impacting cancer treatment and patient care.

United States

Vivace Therapeutics is a venture-backed, oncology-focused portfolio-based drug discovery and development company, based in San Mateo, California. Its programs include both small molecule programs targeting the YAP pathway, and bi-specific programs. For more information on the company, please visit the company website www.vivacetherapeutics.com.

The company's scientific founders are Dr. Kun-liang Guan of UCSD, Dr. Bin Liu of UCSF and Dr. Sheng Ding of UCSF.

Vivace Therapeutics

Company Details